| Previous close | 101.20 |
| Open | 74.75 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 74.75 - 75.65 |
| 52-week range | 74.75 - 75.65 |
| Volume | 229 |
| Avg. volume | N/A |
| Market cap | 3.532B |
| Beta (3Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.99 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
LUND, Sweden , Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly ...
- Buvidal® is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents LUND, Sweden , Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that ...